Sandoz Inc. is moving forward with an appeal following a decision from a Virginia federal court, which concluded that Sandoz should have previously addressed claims against Amgen involving competitive practices related to the Enbrel biosimilar. This development further complicates the ongoing legal tension between the two pharmaceutical giants.
The appeal arises from a broader dispute where Sandoz argues that Amgen has engaged in anti-competitive behavior by blocking the entry of biosimilar versions of its rheumatoid arthritis treatment, Enbrel. According to the ruling, which Sandoz is contesting, the claims should have been part of a prior patent litigation, potentially limiting Sandoz’s options to challenge Amgen’s strategies now.
Amgen’s Enbrel is one of the most lucrative biologic drugs, generating significant revenue. The legal battle over its biosimilar versions reflects broader industry challenges where biosimilar manufacturers often face delays caused by extended patent protections and strategic patenting.
This case is part of a larger trend in the pharmaceutical industry where competition is often hampered by intricate patent landscapes. The Federal Trade Commission has expressed concerns about such practices, noting that they can keep drug prices high by delaying the introduction of cheaper alternatives.
This appeal by Sandoz could have broader implications, not just for the company, but for the industry as a whole, as it tests the boundaries of patent law and competition regulations. If successful, it might encourage other biosimilar manufacturers to pursue similar legal strategies.
For further details on the case, see more from Law360. Additional insights into the impact of this case can be found in reports from the Federal Trade Commission, which highlight the broader economic and legal dynamics at play.